RNA, U7 small nuclear 165 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-165P profile across patient tissues and cancer cell-line models. RNU7-165P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU7-165P is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, RNU7-165P RNA expression shows 10,610 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, PRAD, and SARC as cancer lineages where RNU7-165P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-165P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-165P survival associations across molecular data types. RNU7-165P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-165P RNA expression–survival associations across cancer types. High RNU7-165P expression shows unfavorable associations in KIRC, LIHC, TGCT, THCA and SKCM, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU7-165P RNA expression.
This table summarizes RNU7-165P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-165P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-165P shows lower tumor expression in PRAD and higher tumor expression in LUSC. The PRAD box plot shows higher RNU7-165P RNA expression in normal versus tumor tissue (log2 FC = −0.609, t-test p = .001).
This table shows molecular features associated with RNU7-165P in patient tissues and cancer cell lines. In patient samples, RNU7-165P shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
